Lentiviral Vectors and Adeno-Associated Virus Vectors: Useful Tools for Gene Transfer in Pain Research

CHEN-XI ZHENG,1 SHENG-MING WANG,1 YUN-HU BAI,3 TING-TING LUO,2 JIA-QI WANG,1 CHUN-QIU DAI,1 BAO-LIN GUO,1 SHI-CHENG LUO,1 DONG-HUI WANG,1 YAN-LING YANG,3* AND YA-YUN WANG1*

1Department of Anatomy, Histology and Embryology, K.K. Leung Brain Research Centre, The Fourth Military Medical University, Xi’an 710032, China
2Department of Neurobiology and Collaborative Innovation Center for Brain Science, School of Basic Medicine, The Fourth Military Medical University, Xi’an 710032, China
3Department of Hepatobiliary Surgery, Xi-Jing Hospital, The Fourth Military Medical University, Xi’an 710032, China

ABSTRACT

Pain, especially chronic pain, has always been a heated point in both basic and clinical researches since it puts heavy burdens on both individuals and the whole society. A better understanding of the role of biological molecules and various ionic channels involved in pain can shed light on the mechanism under pain and advocate the development of pain management. Using viral vectors to transfer specific genes at targeted sites is a promising method for both research and clinical applications. Lentiviral vectors and adeno-associated virus (AAV) vectors which allow stable and long-term expression of transgene in non-dividing cells are widely applied in pain research. In this review, we thoroughly outline the structure, category, advantages and disadvantages and the delivery methods of lentiviral and AAV vectors. The methods through which lentiviral and AAV vectors are delivered to targeted sites are closely related with the sites, level and period of transgene expression. Focus is placed on the various delivery methods applied to deliver vectors to spinal cord and dorsal root ganglion both of which play important roles in primary nociception. Our goal is to provide insight into the features of these two viral vectors and which administration approach can be chosen for different pain researches. Anat Rec, 301:825–836, 2018.

V© 2017 The Authors. The Anatomical Record published by Wiley Periodicals, Inc. on behalf of American Association of Anatomists.

Key words: lentiviral vector; AAV vector; spinal cord; DRG; pain

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Grant sponsor: National Natural Science Foundation of China; Grant numbers: 81272555 and 81470843.

Ya-Yun Wang and Yan-Ling Yang contributed equally to this study.

*Correspondence to: Ya-Yun Wang, Department of Anatomy, Histology and Embryology, K.K. Leung Brain Research Centre, The Fourth Military Medical University, Xi’an 710032, China. E-mail: Wang_YaYun_fmmu@163.com

Yan-Ling Yang, Department of Hepatobiliary Surgery, Xi-Jing Hospital, The Fourth Military Medical University, Xi’an, 710032, China. E-mail: Yang_YanLing_fmmu@126.com

Received 4 March 2017; Accepted 19 May 2017.

DOI 10.1002/ar.23723

Published online 17 November 2017 in Wiley Online Library (wileyonlinelibrary.com).

© 2017 The Authors. The Anatomical Record published by Wiley Periodicals, Inc. on behalf of American Association of Anatomists
Pain is an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. Prolonged suffering from pain affects people both physically and psychologically and is one of the main reasons for people to seek medical care and pharmacological treatment. Gene transfer to primary sensory neurons or nociceptors, which can promote the understanding of the cellular mechanisms and pathways involved in nociception, is a promising approach to study pain. Since the expression of transgene is limited at restricted sites in the nervous system, this approach is able to study specific pain-related pathways. In the early 1980s, with vectors based on the Moloney murine leukemia virus (Mo-MLV) being developed, the concept of viral-based tools for gene delivery emerged for the first time (Mann et al., 1983). After that, viral vectors are widely used in the biological sciences, including the study of pain. At present, there are mainly five kinds of viral vectors being widely used. Among them, lentiviral (See Table 1) and adeno-associated virus (AAV) (see Table 2) vectors, which are able to transduce both dividing and non-dividing cells and to maintain long-term stable transgene expression, have gained wide interest for both fundamental and applied purpose. Here, we will summarize recent progress in the research of using lentiviral and AAV vectors for regulating gene expression in neurosciences with special emphasis on pain research.

STRUCTURE OF LENTIVIRAL AND AAV VECTORS

Lentiviral vectors are named by the fact that after the initial infection, there is a long period of time before the disease is started. Among lentiviruses, human immunodeficiency virus (HIV) 1-based vectors were the first to be developed and were most widely used in scientific research (Picanco-Castro et al., 2012). Besides, there are feline immunodeficiency virus (FIV; Da Silva et al., 2010), simian immunodeficiency virus (SIV; Liehl et al., 2007), bovine immunodeficiency virus (BIV; Berkowitz et al., 2001), equine infectious anemia virus (EIAV; Pezet et al., 2006), caprine arthritis-encephalitis virus (Mselli-Lakhal et al., 1998) and so on. Researchers’ opinion on which virus is more safe and efficient is inconsistent. Generally speaking, viral vectors are combined of different plasmids, which can be classified into two parts, the packaging system required for viral particle formation and infectivity and the transfer vector consisting of cis-acting sequences sufficient to mobilize the viral genome. The transgene of interest is loaded on the latter which has been deprived of viral open reading frames (ORFs). HIV-1-based vectors are used as examples to describe the structure of lentiviral vectors. Till now, there have been three generations of lentiviral vectors, the first and the second consisting of three plasmids while the third composed of four plasmids (Picanco-Castro et al., 2012). Here we will only discuss the structure of the third generation of lentiviral vectors which are now widely used. The packaging system involves three plasmids, which provide the required trans-acting factors, namely Gag-pol, Rev, and an envelope protein, respectively. A variety of envelope proteins can be used to form pseudotypes of lentiviral vectors. Vesicular stomatitis virus protein G (VSV-G), one commonly used envelope protein, can incorporate into the viral membrane, enabling the vectors to transduce a broad range of cell types. Another plasmid is the transfer vector which contains the transgene to be delivered and contains all the cis-acting sequences required for genomic RNA production and packaging. Some researchers suggest that there is a fourth generation of lentiviral vectors, which can regulate the expression of the target gene, enormously increasing transduction efficiency and safety. The tetracycline-dependent transcriptional regulatory system is one of the best studied systems with proven efficiency both in vitro and in vivo (Sigl et al., 2014).

AAV, a member of dependovirus subfamily, is a single-stranded DNA parvovirus with a genome approximately 4.7 kb. AAV depends on other viruses such as adenovirus or herpes simplex viruses to complete its life cycle (Tseng & Agbandje-McKenna, 2014). Compared with other virus vectors, the structure of AAV vectors is relatively simple. There are three ORFs in the genome flanked by inverted terminal repeats which act as the viral origin of replication and packaging signal (Nonnenmacher & Weber, 2012). Four nonstructural proteins (Rep 78, Rep 68, Rep 52, and Rep 40) which are involved in the replication, transcription, assembly and genomic integration are encoded by the rep ORF. Three structural proteins (VP 1, VP 2, and VP 3) are encoded by the cap ORF. Besides, there is an assembly activating protein encoded by an ORF present as an alternate reading frame within the cap gene (Sonntag et al., 2010; Sonntag et al., 2011). The production of AAV vectors is through replacing rep and cap by inserting the transgene into the inverted terminal repeats with a promoter.

LENTIVIRAL VECTORS NOT DERIVED OF HIV

Pain researches utilizing lentiviral vectors not based on HIV is rare. Here, we will only discuss the application of SIV-, EIAV-, and FIV-based lentiviral vectors in pain study. SIV-based vectors pseudotyped VSV-G, the amphotropic murine leukemia virus (MLV4070Aenv), the lymphocytic choriomeningitis virus (LCMV-GP), the Ross River virus (RRV-GP) and the rabies virus (RV-G) were used both in vitro and in vivo experiments (Liehl et al., 2007). Although each pseudotype exhibits infectivity for neuronal as well as glial cells in primary mouse brain cultures, only vectors pseudotyped with VSV-G can infect both neurons and glial cells in vivo while others preferentially transduced neuroglial cells. Besides, VSV-G pseudotypes exhibited high transduction efficiency restricted to the injected brain region while LCMV-GP and RV-G pseudotypes showed moderate efficiency and MLV4070Aenv and RRV-GP are inefficient. Moreover, deletion of the central polypurine tract sequence from the VSV-G-pseudotyped SIV transfer vector decreased the transduction efficiency in vivo by four-fold, and these vectors were no longer able to infect neuronal cells in vivo. Results above indicate that SIV vectors can be used as gene delivery vehicles for central nervous system (CNS; Liehl et al., 2007).

As to EIAV-based lentiviral vectors pseudotyped with VSV-G, they are capable of transducing both glial and neuronal cells after intraspinal administration. However, compared with HIV-based vector which transduced mainly glial cells, EIAV-based vector transfected mainly neuronal cells (Georgievska et al., 2004; Wong et al., 2004; Pezet et al., 2006).
FIV-based lentiviral vectors were used in several studies of pain. In a study delivering viral vectors to the rostral ventromedial medulla (RVM), fluorescence microscopy of brain tissue sections for green fluorescence protein (GFP) expression revealed that these vectors predominantly infected neurons located in RVM (Dull et al., 1998). The above results further prove that FIV viral vectors with VSV-G envelope transduce predominantly neurons, rather than non-neuronal cells (Alisky et al., 2000; Da Silva et al., 2010) and local neurons rather than distant neurons. Besides, there are several studies using FIV-based lentiviral vectors in the research of temporomandibular joint pain (Lai et al., 2006; Kyrkanides et al., 2007). Intraarticular injection of these vectors can infect a subset of primary sensory neurons of the ipsilateral trigeminal ganglion presumably following uptake of the lentiviral vector by peripheral nerve fibers and retrograde transportation to the nucleus. This delivery method can avoid the invasiveness and morbidity of neurosurgical procedures and address the location of pain origin instead of randomly covering an expansive area of sensory input. Transgenic animals serving as a model for long-term studies of arthritis can be created with FIV-based lentiviral vectors (Lai et al., 2006), which may potentially provide a platform for the transfer of anti-nociceptive genes for the management of temporomandibular joint pain.

DIFFERENT SEROTYPES OF AAV VECTORS AND THEIR TISSUE TROPISM

At present, more than 100 AAV genomic isolates and 13 human and non-human serotypes have been discovered (Tseng & Agbandje-McKenna, 2014). Here we will discuss six kinds of AAV vectors which have been used in the study of pain.

Compared with other serotypes, AAV serotype 2 (AAV2) vectors have been most deeply studied and most widely applied with high safety, broad host range and high transduction efficiency (Miyake et al., 2012). Besides, AAV2 vectors which can transduce neural cells efficiently and stably with minimal toxicity are excellent gene delivery tools for studies on nervous system (Tenenbaum et al., 2004). A variety of regions of the brain and spinal cord can be transduced by AAV2 vectors (Burger et al., 2005).

AAV serotype 5 (AAV5) vectors pseudotyped with viral capsids from serotype 2 have high proneness for peripheral neurons and can result in long-term and stable expression of transgene with little immunogenicity (Beutler, 2010). Besides, efficient and persistent transduction of neurons in dorsal root ganglion (DRG) can be achieved by AAV5 vectors (Marohn et al., 2010).

AAV serotype 6 (AAV6) vectors can transduce sensory fiber following intravenous administration (Towne et al., 2008) and have high affinity for neurons after direct injection into the CNS (Azeredo da Silveira et al., 2009). It is typical for rAAV2/6 to result in liver transduction which reflects leakage of the vector from the injection site into the blood. However, transgene expression was not detected in liver when rAAV2/6 is administered through sciatic nerve injection (Towne et al., 2009).

AAV serotype 8 (AAV8) vectors exhibited more efficiency and wider distribution of transduced cells in the CNS than AAV2 vectors (Broekman et al., 2006). Besides, self-complementary AAV8 can be useful tools for delivering transgene into the DRG (Storek et al., 2008). In addition, the gene transfer of AAV8 to gray matter is more likely from retrograde transport through nerve terminals since it is difficult for AAV8 vector to cross blood–brain barrier (BBB) even in neonatal stage. AAV serotype 9 (AAV9) vectors is another promising vectors for transgene delivery which can produce long-term gene expression after one-time injection (Hester et al., 2009; Lin et al., 2011). Besides, there is little immunogenicity and toxicity as to the utility of AAV9 (Foust et al., 2009). Compared with AAV8 vectors, AAV9 is more efficient in crossing the BBB and is able to deliver transgene to brain and spinal cord after intravenous vector injection (Foust et al., 2009).

However, the retrograde transport from muscle to nerve of AAV9 is much poorer than AAV8. AAVrh20, a simian AAV serotype, is recently isolated by polymerase chain reaction-based screening of host genomes using primers specific to conserved regions of the cap gene (Asokan et al., 2012). AAVrh20 transduced the highest number of brain cells out of a panel of AAV serotypes including AAV8 when it was injected into the rat striatum (Lawlor et al., 2009). Besides, intrathecal injection of AAVrh20 resulted in a robust transduction of the primary sensory neurons in DRG, higher than that of AAV8. When injected into the rat sciatic nerve, AAVrh20 led to significantly higher transduction rates of DRG neurons compared to that of AAV1 (Pleticha et al., 2014). Therefore, AAVrh20 is likely to be a new promising AAV serotype applied in pain study.

There is differential tissue tropism among different AAV serotypes, which may be related to differential expression of cell-surface molecules required for entry of AAV vectors. As to AAV2 and AAV6, the tissue tropism is dependent on delivery methods. For sciatic nerve and intrathecal injection, greater than 90% of transduced cells are small to medium sized nociceptive neurons. Besides, nerve fibers transduced through sciatic nerve and intrathecal injection were located almost exclusively within the superficial lamina I and II of the dorsal horn (DH) whereas central terminals of DRG neurons transduced by intramuscular and subcutaneous administration were within deeper lamina (Towne et al., 2009). AAV2 intrathecally administered into spinal cord appeared to predominantly infect meningeal cells surrounding the cerebrospinal fluid space (Milligan et al., 2005). In addition, direct injection of AAVrh20 to DH leads to transduction of neurons which penetrate into the spinal DH and terminate predominantly in superficial DH lamina, as well as in the dorsal columns and deeper lamina III-V (Yu et al., 2013). When AAV5 and AAV8 were intrathecally injected through lumbar puncture, GFP labeled fibers were seen predominantly in deeper lamina of DH at cervical, lumbar, and sacral level but restricted to the dorsal columns and Clarke's columns in thoracic spinal cord. Besides, AAV5 and AAV8 vectors preferentially transduced larger diameter DRG neurons in the dorsal columns, which commonly signal innocuous stimuli, but may also carry pain signals in allodynic conditions (Sun et al., 2001). In addition, the least concentration of GFP labeling was in lamina I (substantia gelatinosa) at all levels of the spinal cord, which may be due to the limited targeting of neurons smaller than 22 μm, especially IB4-binding neurons. Therefore, AAV5 and AAV8 could be used for targeting IB4-negative neuronal populations (Vulchanova et al., 2010).
Intrathecal Injection
Clinically, intrathecal administration of analgesics is commonly used to reduce pain at the level of the spinal cord. In pain research, intrathecal injection is also a classic method which is widely applied to deliver lentiviral vectors to the spinal cord with minor injury of the spinal parenchyma and little behavioral alterations (Luo et al., 2014; He et al., 2013; Zou et al., 2011). As early as in 1976, Yaksh and Rudy, (1976) described the implantation of intrathecal catheters for the first time. Usually, in studies using models of neuropathic pain, animal are allowed to recover for 3 days after implantation and it is necessary to monitor the general state of animals during this period (Sun et al., 2012). There are no significant changes of the general behavior of animals, such as weight, intake of food and water and reactive ability after intrathecal injection.

Intraparenchymal Injection
Intraparenchymal microinjection of lentiviral vectors which can lead to highly localized and long-term in vivo expression of transgene in the spinal cord is of great interest in the study of pain mechanisms at the spinal cord level (Pezet et al., 2006; Meunier et al., 2007; Meunier et al., 2008; Dominguez et al., 2010; Takasu et al., 2011). Compared with intrathecal administration, which causes diffusion of the viral suspension to the DRG, transgene expression can be anatomically restricted to the selected area of spinal cord by this method with no diffusion to contralateral spinal cord, DRG or brain stem (Meunier et al., 2007; Meunier et al., 2008). There is even no diffusion between white and grey matter. Besides, in the ipsilateral spinal cord, a large part of the lumbar enlargement (the injection site) can be infected by the vector specifically 0.5 mm along the medial/lateral axis (gray matter), 0.6–1 mm along the dorsoventral axis (DH) and 3–4 mm along the rostro-caudal axis (Meunier et al., 2008). Moreover, the method is relatively non-invasive with minor injury of the spinal parenchyma and no disturbance of the spinal cord homeostasis. Absence of significant biochemical alteration is supported by the lack of behavioral changes. In addition, several studies have found that the main target of this method is glial cell, making it an attractive tool for the study of spinal glia role in chronic pain (Meunier et al., 2007; Meunier et al., 2008; Zhang et al., 2013).

Intraneural Injection
Intraneural injection using retrograde axonal transport is another way to induce transgene expression of specific cell populations in spinal cord. According to the remote viral gene delivery model (Boulis et al., 2003), HIV-1 vector pseudotypes bearing different envelop glycoproteins were injected into the crushed sciatic nerve of rats (Federici et al., 2009). Results showed that HIV-based lentiviral vectors pseudotyped with the Rabies PV glycoprotein might provide important vehicles for CNS targeting by peripheral injection in the treatment of pain.

Intramuscular Injection
Intramuscular injection of lentiviral vectors pseudotyped by Rabies G has demonstrated efficient transduction to spinal cord motor neurons but limited transduction to peripheral sensory neurons via retrograde transport (Mazaraki, 2001).

Intravenous Injection
Intravenous injection of lentiviral vectors pseudotyped by Rabies G has demonstrated efficient transduction to spinal cord motor neurons but limited transduction to peripheral sensory neurons via retrograde transport (Mazaraki, 2001).

Intrathecal Injection
As a promising approach for studying spinal mechanisms of nociception, intrathecal injection of AAV vectors could transfer genes into spinal cord with high safety and high success rate (Milligan et al., 2005; Kao et al., 2010; Vulchanova et al., 2010; Hirai et al., 2012). Besides, intrathecal injection through lumbar puncture which is applied clinically as well as for basic neuropharmacological research, offers a much less invasive route of administration for viral vector-mediated gene transfer (Storek et al., 2006; Vulchanova et al., 2010). Intravenous mannitol pretreatment can be used to facilitate the access of AAV vectors to the spinal cord (Vulchanova et al., 2010). However, the expression of transgene at spinal cord is always accompanied with the retrograde transport of transgene into the DRG (Kao et al., 2010).

Intraparenchymal Injection
Intraparenchymal injection into the spinal cord DH can result in significant transduction of neurons (Eaton et al., 2002; Garraway et al., 2007; Chen et al., 2010). The expression of GFP was confined to the ipsilateral DH, with minimal expression detected in the ipsilateral ventral horn or on the contralateral side. No deficits in motor function were detected in any of the injected mice (Fairbanks, 2003). Besides, cellular toxicity was not observed at both the light microscope and ultrastructural levels. Although this method is convenient for pain research, it is not ideal for clinical use.

Intraneural Injection
In 2003, Kaspar et al., (2003) first reported retrograde transport of AAV vectors from muscle to the spinal cord. After that, researchers have explored more serotypes of AAV vectors such as AAV1, 2, 5, 8, and 9 for retrograde transport from muscle to nerve (Federici & Boulis, 2007; Foust et al., 2008; Hollis II et al., 2008; Foust et al., 2009). After injection of AAV8 vectors to the tibialis anterior and gastrocnemius muscles of adult mice, most transduced cells were seen in white matter in the spinal cord and were found in lower part of the spinal cord. However, two months after delivery, transduced cells were detected in the upper portions such as cervical and thoracic segments besides the lower ones. Three months post-injection neurons in brain especially brain stem were also transduced (Zheng et al., 2010). Moreover, though injected into unilateral muscle, transduced cells were found in bilateral DRG, bilateral spinal cord, and brain stem.
Subarachnoid Injection

One week after subarachnoid injection, enhanced GFP (EGFP)-labeled neurons appeared in the DH and doubled by 3 weeks. Most of them were located in laminae I–III of the DH while some were located in lamina IV. Labeled cells were found in spinal cord sections up to 2 mm away from either side of the injection site; EGFP-labeled fibers could be seen up to 6 mm away from the injection site. However, none of the L4–L6 DRGs on either side of the spinal cord were labeled (Xu et al., 2003).

Intraperitoneal Injection

When AAV8 vectors were intraperitoneally injected into neonatal mice, the majority of transduced cells were located in white matter in the spinal cord. Besides, there were more transduced cells in the lower spinal cord such as lumbar segment than the higher ones such as cervical segment. In addition, DRG neurons were also infected by AAV8 vectors (Zheng et al., 2010).

Intraneural Injection and Intravenous Injection

AAV2 vectors were injected through a needle inserted into the superficial lamina of L4–5 DH along with the root entry at a depth of 220–250 μm with a micromanipulator (Cui and Bazan, 2010). Changes of behavior started only 48 hr after injection and lasted for 7 days. AAV9-mediated glial glutamate transporter-1 overexpression in spinal cord was achieved through injection via tail vein (Hester et al., 2009).

Direct Injection

Direct injection which is well tolerated in both human and rodent subjects is a direct microinjection technique to reliably and safely deliver AAV vectors selectively into individual DRGs. This method can genetically modify segmentally restricted populations of peripheral sensory neurons, including their central processes and presynaptic terminals in the superficial lamina of the spinal cord DH (Yu et al., 2013; Fischer et al., 2014). Besides, the transfected neurons are mainly located on the ipsilateral DRG, which is superior to intrathecal delivery when restricting the spread of vector is desired (Sakai et al., 2013; Samad et al., 2013). However, some showed that the requisite surgery for viral delivery to L4 DRG is accompanied by small transient mechanical and thermal sensitization (Samad et al., 2013).

Intrathecal Injection and Intrathecal Injection through Lumbar Puncture

Intrathecal injection is a safe, easy and efficient method for delivering AAV vectors to DRG (Kao et al., 2010; Chen et al., 2014). The normal body weight, normal locomotion and somatosensory perceptions of injected animals were not disturbed. It does not damage the tissues histologically or alter the expression of unrelated endogenous mRNAs in the spinal cord and DRG (Hirai et al., 2012). Besides, this delivery method is minimally invasive, clinically applicable and is devoid of unwanted abnormalities in mechano-sensation or pain perception. Another advantage of this method is that with larger number of cells transduced, it allows better discrimination of changes in behavioral studies (Tenenbaum et al., 2004). However, it has to be noted that the needle remain at midline and be slowly inserted underneath the dura and further advanced in the subarachnoid space. Nevertheless, since AAV vectors intrathecally injected into DRG can transduce both spinal cord and DRG, the main drawback of this method is lack of specificity (Pleticha et al., 2014).

Compared with direct tissue injection methods (intraparenchymal or intraneural) or intrathecal injection through an atlanto-occipital catheter, which require requisite surgery and may cause inflammation and tissue damage, acute intrathecal delivery through lumbar puncture is minimally invasive with no requirement of surgery or catheter maintenance (Vulchanova et al.,...
| Pain model or normal | Study sites | Delivery method | Target gene | Reference |
|----------------------|-------------|----------------|-------------|-----------|
| Inflammatory pain    | Spinal cord | Intrathecal injection | NF-κBp65 | Luo et al. (2014) |
| Neuropathic pain     | DRG         | Spinal nerve injection | Tumor necrosis factor-α | Ogawa et al. (2014) |
|                      | Spinal cord | Intrathecal injection | Human interleukin-10 | He et al. (2013) |
| Chronic constriction | Intraparenchymal injection | NF-κBp65 | Sun et al. (2012) |
| injury               |             | Protein kinase C isoform γ | | Zou et al. (2011) |
|                      | Spinal cord | Intraparenchymal injection | Cytokine signaling 3 | Dominguez et al. (2010) |
| Normal               | Spinal cord | Intraparenchymal injection | IsBα | Meunier et al. (2007) |
|                      |             | Chemokine (C-X-C motif) ligand 1 | | Zhang et al. (2013) |
|                      | DRG         | Direct injection | Glial cell line-derived neurotrophic factor | Takasu et al. (2011) |
|                      |             | Glial cell line-derived neurotrophic factor | | Pezet et al. (2006) |
|                      | DRG         | Direct injection | Glial cell line-derived neurotrophic factor | Takasu et al. (2011) |
|                      | Spinal cord | Intraneural injection | EGFP | Federici et al. (2009) |
|                      | Intraparenchymal injection | EGFP | Meunier et al. (2007) |
|                      | DRG         | Direct injection | EGFP | Yu et al. (2013) |
| Pain model or normal | Study sites | AAV serotype | Delivery method | Target gene | Reference |
|----------------------|-------------|--------------|----------------|-------------|-----------|
| **Inflammatory pain** | DRG Spinal cord | AAV6 and AAV8 AAV2 | Intrathecal injection | Syntaxin 8 | Chen et al. (2014) |
| **Neuropathic pain** | DRG | AAV6 AAVrh20 and AAV1 | Intrathecal injection (convection-enhanced delivery, CED) | MiR-7a | Sakai et al. (2013) |
| **Chronic constriction injury (CCI)** | DRG | AAV6 AAV8 | Intrathecal injection through lumbar puncture | Prepro-β-endorphin | Storek et al. (2008) |
| **Spinal nerve ligation (SNL)** | DRG | AAV6 AAVrh20 and AAV1 | Intrathecal injection through lumbar puncture | Sodium channel Na,1.3 GTP cyclohydrolase I | Samad et al. (2013) |
| **Spared nerve injury (SNI)** | DRG | AAV2 | Direct injection | GTP cyclohydrolase I | Kim et al. (2009) |
| **Bennett model and Gazelius model** | Spinal cord | AAV2 | Intraneural injection | Agrin | Cui et al. (2010) |
| **Normal** | DRG and spinal cord | AAV2 | Intrathecal injection | μ-opioid receptor | Kao et al. (2010) |
| | AAV5 and AAV8 | | Intrathecal injection through lumbar puncture | GFP | Vulchanova et al. (2010) |
| | AAV8 | | Intraperitoneal injection | GFP or LacZ | Zheng et al. (2010) |
| | AAV9 | | Intramuscular injection | GFP or LacZ | Zheng et al. (2010) |
| | Spinal cord | AAV2 | Intrathecal injection | Superoxide dismutase-1 (SOD1) | Hirai et al. (2012) |
| | AAV1, 2, and 5 | | Intrathecal injection through lumbar puncture | Mu-opioid receptors S196A (MOR S196A) | Chen et al. (2010) |
| | | | Subarachnoid injection | EGFP | Xu et al. (2003) |
| | | | Intrathecal injection through lumbar puncture | EGFP | Storek et al. (2006) |
Besides, this method can be applied in clinic as well as in basic neuropharmacological research (Storek et al., 2008). In addition, intravenous mannitol pretreatment can be used to increase the access of viral particles delivered intrathecally via lumbar puncture. Mannitol, which can control intracranial pressure and disrupt the intercellular tight junctions between endothelial cells of the CNS microvasculature, can be used intravenously to facilitate chemotherapeutic drug delivery to the CNS (Kroll & Neuwelt, 1998). The enhancement of intraparenchymal diffusion of AAV vectors have been achieved in brain, spinal, and DRG (Mastakov et al., 2002; Fu et al., 2003; Vulchanova et al., 2010).

**Sciatic Nerve Injection**

Although the method of direct injection is well-established, the requirement of invasive surgery of removing part of the spinal vertebra may cause unwanted nerve injury and side-effects. Besides, the efficiency of intrathecal administration is impaired by reduced effectiveness of gene transfer and poorer target specificity. Compared with these two methods, delivery through the sciatic nerve, which directly targets the axons of primary sensory or motor neurons and reaches the cell soma by means of retrograde axonal transport efficiently but less invasively, is an excellent route for gene transfer to the DRG (Gu et al., 2005; Iyer et al., 2014). Rats showed no signs of paresis and immune response after AAV vectors were injected into their sciatic nerve, suggesting that there was no permanent nerve damage associated with the procedure. Since injection of the sciatic nerve can be performed unilaterally, the non/vehicle-treated side can serve as a useful internal control for behavior or histology (Kim et al., 2009).

Convection-enhanced delivery (CED) which uses bulk flowas instead of simple diffusion to deliver macromolecules into a solid tissue has been applied to optimize vector distribution in the central and peripheral nervous system (Chen et al., 2011). Although the transduction of intraneural CED and intrathecal injection is equally high, the former can improve the anatomical selectivity of AAV vectors and the transduction was confined to the DRG of the injected peripheral nerve with no evidence of gene expression in the neighboring or contralateral DRG. However, hyperosmotic diluent did not further improve the transduction efficiency of AAV for the intraneural route (Pleticha et al., 2014).

**Subcutaneous Delivery**

Several studies used subcutaneous administration to deliver AAV vectors into DRG. Three weeks after subcutaneous delivery into the ventral or dorsal skin of the hind foot, there were no EGFP-positive cells in the DRGs of 3-week-old rats while EGFP-labeled cells were observed in the ipsilateral DRGs of 1-week-old rats (Xu et al., 2003). Age seems to influence the efficiency of this method. Others administering AAV6 through the middle and lateral plantar surface of the hind foot observed low efficiency of transduction in the DRGs (Towne et al., 2009). Genetical modification of AAV system can enhance the tropism of AAV to neuron cell bodies after being taken up by axons, which would further
strengthen the efficiency of subcutaneous AAV administration to DRGs.

**Intramuscular Delivery**

There are different results as to the efficiency of intramuscular administration of AAV vectors into the DRG. Some researchers injected AAV8 in tibialis anterior and gastrocnemius muscles in one of the hind legs of adult mice and observed long-term and efficient gene transfer in the DRG neurons more on the injected side than the contralateral side (Zheng et al., 2010). However, in another study injecting AAV6 in the triceps surae muscle of the hind limb of mice, low levels of transduction were observed in the DRG (Towne et al., 2009).

**Intraperitoneal Injection**

Intraperitoneal injection which provides extensive and global expression or inhibition of the target gene in all DRG neurons through a simple procedure appears to have potential for pain research. Intraperitoneal administration of AAV9 to neonatal mice lead to highly effective and specific silencing of a target gene in DRG with no major side effects and the suppression effect lasted for more than 3 months post injection (Machida et al., 2013). In another study, efficient and long-term transgene expression was observed in the DRGs of neonatal mice through intraperitoneal injection of AAV8 (Zheng et al., 2010).

**Intravenous Injection**

Compared with other delivery methods, administration through tail vein injection resulted in fewer eGFP-positive cells within the DRG and most of which are large non-nociceptive cells types (Towne et al., 2009).

**ADVANTAGES AND DISADVANTAGES OF LENTIVIRAL**

Lentiviral vectors have various advantages. Lentiviral vectors are capable of infecting a wide variety of dividing and non-dividing cells with high efficiency. Especially, lentiviral vectors have shown an enhanced promeness to transduce terminally differentiated tissues from neuronal origin (Torashima et al., 2006; Meunier & Pohl, 2009) and the normal function of infected cells is not affected both in vitro and in vivo (Torashima et al., 2006). Long term expression of the transgene can be achieved since lentiviral vectors can integrate into the host genome stably (Cockrell & Kafri, 2007). Besides, lentiviral vectors can accommodate relatively large sequences of transgenes (~12–15 kb; Kumar et al., 2001), which extends the scope of their application since most of the currently transferred genes can be cloned into lentiviral vectors. Another advantage is that lentiviral vectors have high safety with minimal immunogenicity and scarcely cause immune reaction in the host. Moreover, a wide variety of different glycoproteins can be used to form pseudotypes with lentiviral vectors, increasing its use value. In addition, lentiviral vector can be compatible with multiple transcriptional promoters, including promoters of housekeeping genes and promoters for specific cells or tissues. In addition, compared with single-stranded AAV vector, lentiviral vectors induce transgene expression more rapidly (Blesch & Tuszynski, 2007).

Despite the above advantages, lentiviral vectors also have many shortcomings. The most serious one is the uncertainty of safety. Since lentiviral vectors cannot insert transgene into specific sites, it may cause non-specific and adverse effects. Besides, insertion mutation can happen which may lead to activation of protooncogene or inhibition of anti-oncogene, increasing the risk of cancer (Hargrove et al., 2008).

**ADVANTAGES AND DISADVANTAGES OF AAV VECTORS**

There are many advantages of AAV vectors. First, AAV vectors can transduce a wide range of tissue and lead to long-term and stable transgene expression in both dividing and non-dividing cell (Li et al., 2005). Second, AAV vectors are highly safe since wild-type AAV has never been shown to cause any human disease (Cao et al., 2000). Besides, AAV vectors seldom cause immune reactions and have low pathogenicity (Lentz et al., 2012). Third, because of their small size and simplicity, the production of AAV vectors is relatively easy and economical and the administration dose of AAV vectors can be higher than other virus vectors. Fourth, compared with other virus vectors, AAV vector seldom inserts into host DNA, which can reduce the possibility of insertional effects (Lentz et al., 2012).

However, there are also some disadvantages of AAV vectors. First, the packaging capacity of AAV vectors is limited to 4.7–5.0 kb in length or 4.4–4.7 kb of unique transgene sequence between the inverted terminal repeats (Grieger & Samulski, 2012), despite the different packaging limitations showed by many researchers. Second, the gene transfer efficiency of AAV vectors is impaired since the complementary DNA has to be synthesized in order to generate a dsDNA template for transcription (McCarty et al., 2001). Third, the prevalence of neutralizing antibodies in the human population increases the risks of immune reaction and decreases the efficiency of AAV vectors. Fourth, the transfection of AAV vectors to specific types of cells and tissue is low, which limits its utility.

**CONCLUSION**

There have been several viral systems developed as vectors for gene transfer. In this review, we have outlined characteristics of lentiviral and AAV vectors and their application in pain research. Lentiviral vectors can induce transgene expression with high efficiency and high safety. Besides, lentiviral vectors can accommodate relatively large sequences of transgenes and form pseudotypes with a wide variety of glycoproteins which enable them to be applied in a variety of areas. Nevertheless, vector integration and insertional mutagenesis have limited the use of lentiviral vectors which needs further improvement of non-integrating transduction. AAV vectors possess several promising attributes as well, including minimal toxicity, stable transduction and simplicity for scalable production. However, limited packaging capacity and relatively low transduction efficiency have been the main disadvantages of AAV vectors. Thus, although lentiviral and AAV vectors are
useful tools for gene delivery in pain research, more efforts should be made in improving the efficiency and safety of these two vectors.

CONFLICT OF INTEREST
The authors have no conflict of interest.

ACKNOWLEDGMENTS
This work was supported by grants from the National Natural Science Foundation of China (81272555, 81470843).

LITERATURE CITED

Aliksy JM, Hughes SM, Sauter SL, Jolly D, Dubensky TW, Staber PD, Chiorini JA, Davidson BL. 2000. Transduction of murine cerebellar neurons with recombinant FIV and AAV5 vectors. Neuroreport 11:2669–2673.

Askana A, Schaffer DV, Samulski RJ. 2012. The AAV vector toolkit: Poised at the clinical crossroads. Mol Therapy 20:699–708.

Azeredo da Silveira S, Schneider BL, Giffaantes-Diaz C, Sage D, Abbas-Terki T, Iwatsubo T, Unser M, Aebischer P. 2009. Phosphorylation does not prompt, nor prevent, the formation of α-synuclein toxic species in a rat model of Parkinson’s disease. Hum Mol Genet 18:872–887.

Berkowitz R, Ilves H, Lin WY, Eckert K, Coward A, Tamaki S, Veres G, Plavec I. 2001. Construction and molecular analysis of gene transfer systems derived from bovine immunodeficiency virus. J Virol 75:3371–3382.

Beutler AS. 2010. AAV provides an alternative for gene therapy of the peripheral sensory nervous system. Mol Ther 18:670–673.

Bleck A, Tuszyński MH. 2007. Transient growth factor delivery sustains regenerated axons after spinal cord injury. J Neurosci 27:10535–10546.

Boulis NM, Noordmans AJ, Song DK, Imperiale MJ, Rubin A, Leone P, During M, Feldman EL. 2003. Adeno-associated viral vector gene expression in the adult rat spinal cord following remote vector delivery. Neurobiol Dia 14:535–541.

Broekman MLD, Comer LA, Hyman BT, Sena-Esteves M. 2006. Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or –2 serotypes for widespread gene delivery to the neonatal mouse brain. Neuroscience 138:501–510.

Burger C, Nash K, Mandel RJ. 2005. Recombinant adeno-associated viral vectors in the nervous system. Hum Gene Ther 16:781–791.

Cao L, Liu Y, During MJ, Xiao W. 2000. High-titer, wild-type free Adeno-associated virus. Mol Ther 2:8463–8471.

Cossutti MA, Kozlovsky I, Feske S, Veres G, Huang J. 2008. Efficient retrograde neuronal transduction utilizing intrathecally administered helper plasmids. J Virol 74:11456–11463.

Chen B, Zhao L, Li X, Ji Y-S, Li N, Xu X-F, Chen Z-Y. 2014. Syn- gene transfer vector for the treatment of neurological disorders: Novel treatment thoughts for ALS. Curr Gene Ther 9:428–433.

Chen X, Astary GW, Mareci TH, Sarntinoranont M. 2011. In vivo high-titer, wild-type free Adeno-associated viral vector increases antinociception of intrathecal morphine. J Pain 6:447–454.

Dominguez E, Mauborgne A, Mallet J, Desclaux M, Pohl M. 2010. SCS-mediated blockade of JAK/STAT3 signaling pathway reveals its major contribution to spinal cord neuroinflammation and mechanical allodynia after peripheral nerve injury. J Neurosci 30:5754–5766.

Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L. 1998. A third-generation lentivirus vector with a conditional packaging system. J Virol 72:8463–8471.

Eaton MJ, Blits B, Ruitenberg MJ, Verhaagen J, Oudega M. 2002. Amelioration of chronic neuropathic pain after partial nerve injury by adeno-associated viral (AAV) vector-mediated over-expression of BDNF in the rat spinal cord. Gene Ther 9:1387–1395.

Fairbanks CA. 2003. Spinal delivery of analgesics in experimental models of pain and analgesia. Adv Drug Deliv Rev 55:1007–1041.

Federici T, Boulis N. 2007. Gene therapy for peripheral nervous system diseases. Curr Gene Ther 7:239–248.

Federici T, Kuttaer R, Zhang X-Y, Kuroda H, Tordo N, Boulis NM, Reiser J. 2009. Comparative analysis of HIV-1-based lentiviral vectors bearing lysosomal glycoproteins for neuronal gene transfer. Genet Vaccines Ther 7:1.

Hargrove PW, Kepes S, Hanawa H, Obenauer JC, Pei D, Cheng C, Gray JT, Neale G, Persons DA. 2008. Globin lentiviral vector insertions can perturb the expression of endogenous genes in beta-thalassemic hematopoietic cells. Mol Ther 16:525–533.

He ZH, Guo Q, Xiao M, He C, Zou W. 2013. Intrathecal lentivirus-mediated transfer of interleukin-10 attenuates chronic constriction injury-induced neuropathic pain through modulation of spinal high-mobility group box 1 in rats. Pain Physician 16:E615–E625.

Hester ME, Foustd KD, Kaspar RW, Kaspar BK. 2009. AAV as a gene transfer vector for the treatment of neurological disorders: Novel treatment thoughts for ALS. Curr Gene Ther 9:428–453.

Hirai T, Enomoto M, Machida A, Yamamoto M, Kuwahara H, Tajiri M, Hirai Y, Sotome S, Mizusawa H, Shinomiya K, Okawa A, Yokota T. 2012. Intrathecal shRNA-AAV inhibits target protein expression in the spinal cord and dorsal root ganglia of adult mice. Hum Gene Ther Methods 23:119–127.

Holmes ER, Kudoya K, Abul-Hajj M, Samulski RJ, Tuszyński MH. 2002. Efficient retrograde neuronal transduction utilizing self-complementary AAV1. Mol Ther 16:296–301.

Hester ME, Foustd KD, Kaspar RW, Kaspar BK. 2009. AAV as a gene transfer vector for the treatment of neurological disorders: Novel treatment thoughts for ALS. Curr Gene Ther 9:428–453.

Hirai T, Enomoto M, Machida A, Yamamoto M, Kuwahara H, Tajiri M, Hirai Y, Sotome S, Mizusawa H, Shinomiya K, Okawa A, Yokota T. 2012. Intrathecal shRNA-AAV inhibits target protein expression in the spinal cord and dorsal root ganglia of adult mice. Hum Gene Ther Methods 23:119–127.

Holmes ER, Kudoya K, Abul-Hajj M, Samulski RJ, Tuszyński MH. 2002. Efficient retrograde neuronal transduction utilizing self-complementary AAV1. Mol Ther 16:296–301.
Iyer SM, Montgomery KL, Towne C, Lee SY, Ramakrishnan C, Deisselho K, Delp SL. 2014. Virally mediated optogenetic excitation and inhibition of pain in freely moving nontransgenic mice. Nat Biotechnol 32:274–278.

Kao JH, Chen SL, Ma HI, Law PY, Tao PL, Loh HH. 2010. Intraarticular Delivery of a Mutant mu-Opioid Receptor Activated by Naloxone as a Possible Antinociceptive Paradigm. J Pharmacol Exp Ther 334:739–745.

Kaspar BK, Llados J, Sherkat N, Rothstein JD, Gage FH. 2003. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301:839–842.

Kim SJ, Lee W II, Lee YS, Kim DH, Chang JW, Kim SW, Lee H. 2009. Effective relief of neuropathic pain by adeno-associated virus-mediated expression of a small hairpin RNA against GTP cyclohydrolase 1. Mol Pain 5:67.

Kroll RA, Neuwelt EA. 1998. Outwitting the blood-brain barrier for therapeutic purposes: Osmotic opening and other means. Neurosurgery 42:1083–1099. discussion 1099-1000.

Kumar M, Keller B, Makabou N, Sutton RE. 2001. Systematic determination of the packaging limit of lentiviral vectors. Hum Gene Ther 12:1893–1905.

Kyrkanides S, Fiorentino PM, Miller J-NH, Gan Y, Lai Y-C, Shaftel S, Puzas JE, Pianigo MC, O’Banion MK, Tallents RH. 2007. Amelioration of pain and histopathological joint abnormalities in the Col1-IL-1beta(XAT) mouse model of arthritis by intraarticular induction of mu-opioid receptor into the temporomandibular joint. Arthritis Rheum 56:2038–2048.

Lai Y-C, Shaftel SS, Miller J-n. H, Tallents RH, Chang Y, Pinkert CA, Oslichowa JK, Dickerson IM, Puzas JE, O’Banion MK, Kyrkanides S. 2006. Intraarticular induction of interleukin-1beta expression in the adult mouse, with resultant temporomandibular joint pathologic changes, dysfunction, and pain. Arthritis Rheum 54:1184–1197.

Lawlor PA, Bland RJ, Mouravlev A, Young D, During MJ. 2009. Efficient gene delivery and selective transduction of glial cells in the mammalian brain by AAV serotypes isolated from nonhuman primates. Mol Ther 17:1692–1702.

Lentz TB, Gray SJ, Samulski RJ. 2012. Viral vectors for gene delivery to the central nervous system. Neurobiol Dis 48:179–188.

Li C, Bowles DE, van Dyke T, Samulski RJ. 2005. Adeno-associated virus vectors: Potential applications for cancer gene therapy. Cancer Gene Ther 12:913–925.

Liehl B, Hlavaty J, Moldzio R, Tonar Z, Unger H, Salmons B, Li C, Bowles DE, van Dyke T, Samulski RJ. 2012. Intracranial viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301:839–842.

Luo JG, Zhao XL, Xu WC, Zhao XJ, Wang JN, Lin XW, Sun T, Fu ZJ. 2014. Activation of spinal NF-kB/p65 contributes to peripheral inflammation and hyperalgesia in rat adjuvant-induced arthritis. Arthritis Rheumatol 66:896–906.

Machida A, Kuwahara H, Mayara A, Kubodera T, Hiroi T, Sunaga F, Tajiri M, Hirai Y, Shimada T, Mizusawa H, Yokota T. 2013. Intraparenchymal administration of AAV9-shRNA inhibits target gene expression in the dorsal root ganglia of neonatal mice. Mol Pain 9:8.

Mann R, Mulligan RC, Baltimore D. 1983. Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 33:155–159.

Mason MBJ, Ehler EM, Eggers R, Pool CW, Hermening S, Huseinovic A, Timmernans E, Blits B, Verhaegen J. 2010. Comparison of AAV serotypes for gene delivery to dorsal root ganglion neurons. Mol Ther 18:715–724.

Mastakov MY, Baer K, Symes CW, Leichtlein CB, Kotin RM. During MJ. 2002. Immunological aspects of recombinant adeno-associated virus delivery to the mammalian brain. J Virol 76: 8446–8454.

Mazarakis ND. 2001. Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Hum Mol Genet 10: 2109–2121.

McCarty DM, Monahan PE, Samulski RJ. 2001. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther 8:1245–1254.

Meunier A, Latremoliere A, Dominguez E, Mauborgne A, Philippe S, Hamon M, Mallet J, Benoliel J-J, Pohl M. 2007. Lentiviral-mediated targeted NF-kB blockade in dorsal spinal cord glia attenuates sciatic nerve injury-induced neuropathic pain in the rat. Mol Ther 15:687–697.

Meunier A, Mauborgne A, Masson J, Mallet J, Pohl M. 2008. Lentiviral-mediated targeted transgene expression in dorsal spinal cord glia: Tool for the study of glial cell implication in mechanisms underlying chronic pain development. J Neurosci Methods 167:148–159.

Meunier A, Pohl M. 2009. Lentiviral vectors for gene transfer into the spinal cord glial cells. Gene Therapy 16:476–492.

Millar ED, Sloane EM, Langer SJ, Cruz PE, Chacur M, Spataro L, Wieseler-Frank J, Hammad SE, Maier SF, Flotte TR, Forsayeth JR, Leinwand LA, Chavez R, Watkins LR. 2005. Controlling neuropathic pain by adeno-associated virus driven production of the anti-inflammatory cytokine, interleukin-10. Mol Pain 1:9.

Miyake K, Miyake Y, Namazaki Y, Shimada T, Hirai Y. 2012. Serotype-independent method of recombinant adeno-associated virus (AAV) vector production and purification. J Nippon Med Sch 79: 394–402.

Mesihi-Lakhal L, Favier C, Da Silva Teixeira MF, Chettar K, Legras R, Roncort F, Verdier G, Mornex JF, Chebloune Y. 1998. Defective RNA packaging is responsible for low transduction efficiency of CAEV-based vectors. Arch Virol 143:681–695.

Nonnenmacher M, Weber T. 2012. Intracellular transport of recombinant adeno-associated virus vectors. Gene Ther 19:649–658.

Ogawa N, Kawai H, Terashima T, Kojima H, Oka K, Chan L, Maega H. 2014. Gene therapy for neuropathic pain by silencing of TNF-alpha expression with lentiviral vectors targeting the dorsal root ganglion in mice. PLoS One 9:e92073.

Pezet S, Krzyzanowska A, Wong L-F, Grist J, Mazarakis ND, Georgievskaya B, McMahon SB. 2006. Reversal of neurochemical changes and pain-related behavior in a model of neuropathic pain using modified lentiviral vectors expressing GDNF. Mol Ther 13: 1101–1109.

Picano-Castro V, de Sousa Russo-Carbolante EM, Tadeu Covas D. 2012. Advances in lentiviral vectors: A patent review. Recent Pat DNA Gene Seq 6:82–90.

Pleticha J, Jeng-Singh C, Rezek R, Zaibak M, Beutler AS. 2014. Intraneuronal convection enhanced delivery of AAVrh20 for targeting primary sensory neurons. Mol Cell Neurosci 60:72–80.

Sakai A, Saitow F, Miyake N, Miyake K, Shimada T, Suzuki H. 2013. miR-7a alleviates the maintenance of neuropathic pain by silencing of GABA receptor expression in dorsal root ganglia from neuropathic rats. PLoS One 8:1248–1254.

Samad OA, Tan AM, Cheng X, Foster E, Dib-Hajj SD, Waxman SG. 2013. MiR-146 regulates proinflammatory cytokines and inhibits spinal neuronal injury in diabetic mice. J Neurosci 33:14994–15005.

Satorg R, Ploner C, Shivalingaiah G, Kofler R, Geley S, Tripp R. 2014. Treating trigeminal neuralgia: A lentiviral-based approach. J Neurosci 34:14159–14164.

Sonntag F, Schmidt K, Kleinschmidt JA. 2009. A viral assembly factor promotes capsid assembly of different adeno-associated virus serotypes. J Virol 85:12686–12697.

Sonntag F, Schmidt K, Kleinschmidt JA. 2010. A viral assembly factor promotes AAV2 capsid formation in the nucleus. Proc Natl Acad Sci U S A 107:10220–10225.

Stoerk B, Harder NM, Banck MS, Wang C, McCarty DM, Janssen WG, Morrison JH, Walsh CE, Beutler AS. 2006. Intrathecal long-term application of a lentiviral vector to the central nervous system.
gene expression by self-complementary adeno-associated virus type 1 suitable for chronic pain studies in rats. Mol Pain 2:4.

Storek B, Reinhardt M, Wang C, Janssen WGM, Harder NM, Banck MS, Morrison JH, Beutler AS. 2008. Sensory neuron targeting by self-complementary AAV8 via lumbar puncture for chronic pain. Proc Natl Acad Sci U S A 105:1055–1060.

Sun H, Ren K, Zhong CM, Ossipov MH, Malan TP, Lai J, Porreca F. 2001. Nerve injury-induced tactile allodynia is mediated via ascending spinal dorsal column projections. Pain 90:105–111.

Sun T, Luo J, Jia M, Li H, Li K, Fu Z. 2012. Small interfering RNA-mediated knockdown of NF-kappaBp65 attenuates neuropathic pain following peripheral nerve injury in rats. Eur J Pharmacol 682:79–85.

Takasu K, Sakai A, Hanawa H, Shimada T, Suzuki H. 2011. Overexpression of GDNF in the uninjured DRG exerts analgesic effects on neuropathic pain following segmental spinal nerve ligation in mice. J Pain 12:1130–1139.

Tenenbaum L, Chitarto A, Lehtonen E, Velu T, Brotchi J, Levivier M. 2004. Recombinant adeno-associated virus delivery to the central nervous system. J Gene Med 6 Suppl 1:S212–S222.

Torashima T, Okoyama S, Nishizaki T, Hirai H. 2006. In vivo transduction of murine cerebellar Purkinje cells by HIV-derived lentiviral vectors. Brain Res 1082:11–22.

Towne C, Pertin M, Beggah AT, Aebischer P, Decosterd I. 2009. Recombinant adeno-associated virus serotype 6 (rAAV2/6)-mediated gene transfer to nociceptive neurons through different routes of delivery. Mol Pain 5:52.

Wong L-F, Azzouz M, Walmsley LE, Askham Z, Wilkes FJ, Mitrophanous KA, Kingsman SM, Mazarakis ND. 2004. Transduction patterns of pseudotyped lentiviral vectors in the nervous system. Mol Ther 9:101–111.

Yu H, Fischer G, Ferhatovic L, Fan F, Light AR, Weihrauch D, Sapunar D, Nakai H, Park F, Hogan QH. 2013. Intraganglionic AAV6 results in efficient and long-term gene transfer to peripheral sensory nervous system in adult rats. PLoS One 8:e61266.

Zhang Z-J, Cao D-L, Zhang X, Ji R-R, Gao Y-J. 2013. Chemokine contribution to neuropathic pain: Respective induction of CXCL1 and CXCR2 in spinal cord astrocytes and neurons. Pain 154:2185–2197.

Zheng H, Qiao C, Wang C-H, Li J, Li J, Yuan Z, Zhang C, Xiao X. 2010. Efficient retrograde transport of adeno-associated virus type 8 to spinal cord and dorsal root ganglion after vector delivery in muscle. Hum Gene Ther 21:87–97.

Zou W, Song Z, Guo Q, Liu C, Zhang Z, Zhang Y. 2011. Intrathecal lentiviral-mediated RNA interference targeting PKCγ attenuates chronic constriction injury-induced neuropathic pain in rats. Hum Gene Ther 22:465–475.